Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Lifted by HealthInvest Partners AB

HealthInvest Partners AB boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 67,763 shares of the company’s stock after acquiring an additional 7,156 shares during the period. Neurocrine Biosciences comprises approximately 4.3% of HealthInvest Partners AB’s portfolio, making the stock its 8th largest position. HealthInvest Partners AB owned approximately 0.07% of Neurocrine Biosciences worth $9,288,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NBIX. State Street Corp grew its position in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after acquiring an additional 539,936 shares during the last quarter. Jennison Associates LLC grew its position in Neurocrine Biosciences by 145.1% during the 4th quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock worth $112,025,000 after purchasing an additional 485,894 shares during the last quarter. Los Angeles Capital Management LLC grew its position in Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after purchasing an additional 363,863 shares during the last quarter. Braidwell LP increased its stake in Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after purchasing an additional 158,665 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in shares of Neurocrine Biosciences by 23.9% in the third quarter. BNP Paribas Financial Markets now owns 533,324 shares of the company’s stock valued at $61,450,000 after buying an additional 102,715 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the topic of a number of research reports. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. HC Wainwright reiterated a “buy” rating and issued a $185.00 target price on shares of Neurocrine Biosciences in a research note on Friday. Morgan Stanley upped their price target on Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Finally, Wedbush dropped their price objective on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $166.90.

Neurocrine Biosciences Trading Up 3.9 %

Neurocrine Biosciences stock opened at $120.69 on Monday. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The stock has a market cap of $12.03 billion, a PE ratio of 36.68, a P/E/G ratio of 0.77 and a beta of 0.33. The stock has a 50-day moving average price of $136.63 and a 200 day moving average price of $129.31.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences announced that its board has initiated a share buyback plan on Friday, February 21st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 5,844 shares of Neurocrine Biosciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total value of $681,936.36. Following the transaction, the director now owns 521,618 shares in the company, valued at $60,867,604.42. This trade represents a 1.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Matt Abernethy sold 1,283 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.87, for a total value of $196,132.21. Following the sale, the chief financial officer now owns 32,681 shares of the company’s stock, valued at approximately $4,995,944.47. The trade was a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 236,600 shares of company stock worth $34,348,261 in the last 90 days. 4.30% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.